Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4923 - Signal transduction pathway activity during neoadjuvant treatment in esophageal adenocarcinomas

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Translational Research

Tumour Site

Oesophageal Cancer

Presenters

Aafke Creemers

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

A. Creemers1, S.L. Meijer2, M. Stoffels3, G.K.J. Hooijer2, L. Holtzer3, H. van Ooijen3, A. Van Brussel3, E.M.G. Aussems-Custers3, M. van Berge Henegouwen4, M.C.C.M. Hulshof5, K.K. Krishnadath6, A. van de Stolpe7, M.F. Bijlsma8, H.W.M. van Laarhoven9

Author affiliations

  • 1 Medical Oncology, Academic Medical Center (AMC), 1105AZ - Amsterdam/NL
  • 2 Pathology, Academic Medical Center (AMC), 1105AZ - Amsterdam/NL
  • 3 Precision And Decentralized Diagnostics, Philips Research, 5656 AE - Eindhoven/NL
  • 4 Surgery, Academic Medical Center, 1105 AZ - Amsterdam/NL
  • 5 Radiotherapy, Academic Medical Center (AMC), 1105AZ - Amsterdam/NL
  • 6 Gastroenterology, Academic Medical Center (AMC), 1105AZ - Amsterdam/NL
  • 7 Research, Philips, 5656 AE - Eindhoven/NL
  • 8 Lexor, Academic Medical Center (AMC), 1105AZ - Amsterdam/NL
  • 9 Medical Oncology, Academic Medical Center (AMC), 1100 DD - Amsterdam/NL
More

Resources

Abstract 4923

Background

Little is known about signaling pathway activity in esophageal adenocarcinomas. Using a new methodology we have delineated the activity of key pathways involved in tumor growth during neoadjuvant treatment. The aim is to use this knowledge to personalize, and thereby improve, treatment strategies.

Methods

We included all patients with esophageal adenocarcinomas between 2004 and May 2013 in the AMC. Paired tumor samples were obtained before start of neoadjuvant chemoradiation therapy according to the CROSS regimen and at surgical resection of the esophagus. Using a custom-built device, digital annotations of whole slide H&E scans were transferred to a hematoxylin-stained slide, which was subsequently deparaffinized. Marked tumor areas were scraped for RNA extraction and qPCR. qPCR data were subjected to stringent QC prior to determining the signaling pathway activity scores of the AR-, ER-, FOXO/PI3K-, HH-, TGF-β- and WNT pathway, using a combined mRNA-Bayesian model-based method (Verhaegh et al, Cancer Res, 2014). Pathway activity scores were correlated to pathological response to treatment (Mandard score).

Results

Based on a test set of esophageal tumor tissue samples, we determined that tumor areas of ≥ 2mm2 were eligible for RNA isolation and pathway activity analysis. We provide a analysis of 288 currently processed samples. FOXO activity was significantly higher in post-treatment resection specimen compared to matched pre-treatment biopsies (p < 0.001). Patients with high FOXO activity in post-treatment resection specimen showed better response to treatment (p = 0.019).

Conclusions

The assessment of pathway activity is feasible on small amounts of tumor. Marked dynamics in FOXO activity are observed during nCRT in esophageal adenocarcinomas. Patients with high FOXO activity post-nCRT show better response to treatment. An active PI3K pathway blocks FOXO transcriptional activity. To increase FOXO transcriptional activity, patients might benefit from the addition of PI3K-inhibitors to the nCRT regimen.

Clinical trial identification

Legal entity responsible for the study

AMC.

Funding

Royal Philips.

Editorial Acknowledgement

Disclosure

M. Stoffels, L. Holtzer, A. Van Brussel: Employee: Royal Philips; Research funding: Royal Philips. H. van Ooijen: Employee: Royal Philips; Patents, royalties or other intellectual property: Royal Philips. E.M.G. Aussems-Custers. A. van de Stolpe: Employee, Funded: Royal Philips. M. van Berge Henegouwen: Research funding: Olympus. M.F. Bijlsma: Research funding: Celgene. H.W.M. van Laarhoven: Consultant: Philips, Celgene, Lilly, Nordic; Unrestricted research funding: Philips, Bayer, BMS, Celgene, Lilly, Merck Serono, MSD, Nordic, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.